Table 1 Treatment-specific transition probabilities for CHB to cured and CHB to inactive carrier transitions
Treatment strategy | CHB to cured and CHB to inactive carrier transitions | First-year reactivation probability (transition from inactive carrier to CHB) | ||||
|---|---|---|---|---|---|---|
CHB to cured (%) | Source | CHB to inactive carrier (%) | Source | Source | ||
LAM | 0.7 | Zhang et al. (2015) | 24.1 | Zhang et al. (2015) | 0.175 | |
LDT | 0.7 | 33.3 | 0.075 | |||
ADV | 1.3 | 18.3 | 0.04 | Hou et al. (2015) | ||
ETV | 1.4 | 25.6 | 0 | Yuen et al. (2011) | ||
TDF | 0.7 | Conservative assumption made for the least effective treatment amongst monotherapies (i.e. LAM/LDT) | 15.5 | Hou et al. (2008) | 0 | Hou et al. (2015) |
LDT + ADV | 0.7 | Sun et al. (2014) | 35.7 | Sun et al. (2014) and Zhang et al. (2015) [derived using LDT and LDT + ADV ratio from Sun et al. (2014)] | 0.01 | Sun et al. (2014) and Zhang et al. (2015) [derived using LDT and LDT + ADV ratio from Sun et al. (2014)] |
LDT + TDF | 4.4 | Piratvisuth et al. (2013) and Zhang et al. (2015) [derived using LDT and LDT + TDF ratio from Piratvisuth et al. (2013)] | 6.1 | Piratvisuth et al. (2013) and Zhang et al. (2015) [derived using LDT and LDT + TDF ratio from Piratvisuth et al. (2013)] | 0 | Piratvisuth et al. (2013) |
No treatment | 0.7 | Assumed to be equal to the least effective treatment (i.e. LDT/LAM) | 9.0 | Shepherd et al. (2006) | 0.03 | Shepherd et al. (2006) |